VC Fund Dossiers

Cetin only looks 3-4 years ahead for exits and won't touch early-stage - 'I am like a goldfish,' he says. They're genuinely hands-on: every team member talks to their portfolio company CEOs at least twice a month. With almost €2bn AUM and 12 unicorns in their portfolio, they've got serious firepower. But they're conservative to a fault - passed on AI hype and blockchain, waiting for 'second wave' opportunities. The real value? Direct access to Allianz's massive customer base and distribution network for strategic partnerships.

Apposite is that rare breed - a genuinely healthcare-obsessed fund that actually knows what it's talking about. Nearly half their LPs are committed to healthcare impact investing, and their portfolio companies have achieved 20%+ annual revenue and employment growth on average - which is solid execution, not just marketing fluff. The Ulthera exit to Merz for up to $600M shows they can deliver returns, and founders consistently praise their hands-on approach. They're small with a flat hierarchy and human touch - think boutique healthcare specialists, not spreadsheet jockeys. The downside? £5M-£20M check sizes and £200M under management means they're playing in a specific sandbox - great if you fit, limiting if you don't. They're genuinely impact-focused, which is refreshing, but also means they'll pass on profitable healthcare plays that don't move the needle on patient outcomes.

Atlantic Bridge is the old guard of European tech - they've been doing cross-border deals since before it was cool. Brian Long and team have serious operator credentials (multiple IPOs, actual chip company exits) which matters when you're pitching deep tech. They're not just check-writers - they genuinely help European companies crack the US market through their Palo Alto office and connections. However, note that Atlantic Bridge gradually exited their entire position in Navitas stock in 2025 despite the company's strong showing that year - they know when to take profits. Their exit track record is legitimately impressive: Movidius to Intel, DecaWave to Qorvo, Blue Data to HPE, Hedvig to Commvault, NuVia to Qualcomm. They're particularly strong in semiconductors and enterprise software, but they move slowly and do serious due diligence.

BaltCap is the Baltic heavyweight you go to when you want an investor who actually knows how to build companies in emerging Europe. Portfolio CEOs rave about their decade-plus partnerships and result-oriented approach, which tells you everything about their post-investment value-add. The recent €100M+ infrastructure fund embezzlement scandal involving partner Šarūnas Stepukonis was a black eye, but their handling shows institutional maturity. They're the rare Eastern European fund that can execute London Stock Exchange take-privates and has genuine multi-decade track record. Their focus on digitization and automation shows they get where markets are heading, not just chasing yesterday's winners.

Cipio is the grown-up in the room when European tech companies need to transition from scrappy startup to serious business. They're not chasing the latest AI hype or throwing money at unproven models - they want companies with €10M+ revenue that need capital and operational expertise to scale. The team has serious operational chops (multiple successful exits, board experience) and isn't afraid of complex deals that provide liquidity to early investors while fueling growth. Founders consistently praise their hands-on approach and M&A expertise. The downside? They're not your Series A darling - if you're pre-revenue or looking for patient capital to figure out product-market fit, look elsewhere.